The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Predictors of major infections in systemic lupus erythematosus
Open accessAbstract
Introduction: Infections commonly complicate the course of systemic lupus erythematosus (SLE). Our aim is to investigate the clinical predictors of major infections in patients with SLE. Methods: A nested case–control study design was used within the prospective Lupus-Cruces cohort. The endpoints of the study were major infections. Cases were defined as patients with a major infection. Two controls (SLE patients without major infections), matched for time of follow-up until the event and age at diagnosis, were selected for each case. Univariate analysis and logistic regression models were used for the analysis of data. Results: Two hundred and forty-nine patients (83 cases, 166 controls) were selected. Eighty-three episodes of major infections were analyzed; E. coli, S. aureus, M. tuberculosis and S. pneumoniae being the most frequent isolates. Univariate analysis identified several variables related with infection: lung and renal involvement, at or previous to the study point; leukopenia at the study point; antiphospholipid antibody-positivity and treatment with prednisone within 3 months previous to the study point, and the dose of prednisone received. Treatment with antimalarials, on the other hand, showed a strong inverse association with major infections. Logistic regression models identified treatment with antimalarials (odds ratio (OR) = 0.06, 95% confidence interval (CI) = 0.02 to 0.18), prednisone dose (OR = 1.12, 95% CI = 1.04 to 1.19) and lung involvement (OR = 4.41, 95% CI = 1.06 to 18.36) as significant and independent predictors of major infections. No significant interactions among these three variables were found. Further adjustment for potential confounders related with antimalarial treatment did not change the results. Conclusions: The risk of major infections in patients with SLE is mostly influenced by treatment. Prednisone treatment, even at moderate doses, increases the risk, whilst antimalarials have a protective effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX
(2007) · Systemic Lupus Erythematosus · doi:10.1016/b978-0-323-04434-9.50060-9 · Cited by 2,928
Cervera, R., Khamashta, M. A., Font, J., Sebastiani, G. D., Gil, A., Lavilla, P., Mejía, J. C., Aydintug, A. O., Chwalinska-Sadowska, H., de Ramón, E., et al. (2003) · Medicine · doi:10.1097/01.md.0000091181.93122.55 · Cited by 1,377
Effects of chloroquine on viral infections: an old drug against today's diseases
Savarino, A., Boelaert, J. R., Cassone, A., Majori, G., & Cauda, R. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00806-5 · Cited by 1,268
Houssiau, F. A., Vasconcelos, C., D'Cruz, D., Sebastiani, G. D., Garrido, E. D. R., Danieli, M. G., Abramovicz, D., Blockmans, D., Mathieu, A., Direskeneli, H., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10461 · Cited by 1,077
Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P., & Khamashta, M. A. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101766 · Cited by 978
Self-citationImmortal time bias in observational studies of drug effects
Suissa, S. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1357 · Cited by 584
Alarcón, G. S., McGwin, G., Bertoli, A. M., Fessler, B. J., Calvo-Alén, J., Bastian, H. M., Vilá, L. M., & Reveille, J. D. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.068676 · Cited by 528
Damage in systemic lupus erythematosus and its association with corticosteroids
Zonana-Nacach, A., Barr, S. G., Magder, L. S., & Petri, M. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200008)43:8<1801::aid-anr16>3.0.co;2-o · Cited by 495
Gladman, D. D., Goldsmith, C. H., Urowitz, M. B., Bacon, P. A., Fortin, P. R., Ginzler, E. M., Gordon, C., Hanly, J. G., Isenberg, D. A., Petri, M., et al. (2000) · PubMed · Cited by 477
Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus
Ruiz-Irastorza, G., Egurbide, M.-V., Pijoan, J.-I., Garmendia, M., Villar, I., Martinez-Berriotxoa, A., Erdozain, J.-G., & Aguirre, C. (2006) · Lupus · doi:10.1177/0961203306071872 · Cited by 411
Self-citationRolain, J.-M., Colson, P., & Raoult, D. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.05.015 · Cited by 401
Pryor, B. D., Bologna, S. G., & Kahl, L. E. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390906 · Cited by 236
The nature and outcome of infection in systemic lupus erythematosus
Gladman, D. D., Hussain, F., Iban, D., & Urowitz, M. B. (2002) · Lupus · doi:10.1191/0961203302lu170oa · Cited by 235
Petri, M., & Genovese, M. C. (1992) · PubMed · Cited by 210
Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients
Bosch, X., Guilabert, A., Pallarés, L., Cervera, R., Ramos-Casals, M., Bové, A., Ingelmo, M., & Font, J. (2006) · Lupus · doi:10.1177/0961203306071919 · Cited by 204
Noël, V, Lortholary, O., Casassus, P., Cohen, P., Généreau, T., André, M.-H., Mouthon, L., & Guillevin, L. (2001) · Annals of the Rheumatic Diseases · doi:10.1136/ard.60.12.1141 · Cited by 199
Sisó, A., Ramos-Casals, M., Bové, A., Brito-Zerón, P., Soria, N., Muñoz, S., Testi, A., Plaza, J., Sentís, J., & Coca, A. (2008) · Lupus · doi:10.1177/0961203307086503 · Cited by 189
Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients.
Duffy, K. W., Duffy, C. M., & Gladman, D. D. (1991) · PubMed · Cited by 175
Infections in outpatients with systemic lupus erythematosus: a prospective study
Zonana-Nacach, A., Camargo‐Coronel, A., Yañez, P., Sánchez, L., Jiménez-Balderas, F. J., & Fraga, A. (2001) · Lupus · doi:10.1191/096120301678416088 · Cited by 135
Jeong, S. J., Choi, H. K., Lee, H. S., Han, S. H., Chin, B. S., Baek, J. H., Kim, C. O., Choi, J. Y., Song, Y. G., & Kim, J. M. (2009) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540902744741 · Cited by 87
Urinary tract infections and lupus erythematosus
Hidalgo-Tenorio, C., Jiménez-Alonso, J., Luna, J. D. D., Tallada, M., Martínez-Brocal, A., & Sabio, J. M. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.006346 · Cited by 39
Quinine sulfate and bacterial invasion
Wolf, R., Baroni, A., Greco, R., Donnarumma, G., Ruocco, E., Tufano, M. A., & Ruocco, V. (2002) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-1-5 · Cited by 24
Wilson (1999) · doi:10.1002/1529-0131(199907)42:7<1309::aid-anr1>3.0.co;2-f
Cited by
Mechanisms of action of hydroxychloroquine and chloroquine:implications for rheumatology
Schrezenmeier, E., & Dörner, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0372-x · Cited by 1,468
Management strategies and future directions for systemic lupus erythematosus in adults
Durcan, L., O'Dwyer, T., & Petri, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30237-5 · Cited by 648
Zhou, D., Dai, S.-M., & Tong, Q. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa114 · Cited by 600
The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment
Listing, J., Gerhold, K., & Zink, A. (2013) · Rheumatology · doi:10.1093/rheumatology/kes305 · Cited by 541
Danza, A., & Ruiz-Irastorza, G. (2013) · Lupus · doi:10.1177/0961203313493032 · Cited by 359
Self-citation
Metadata
- Authors
- Ruiz-Irastorza, G., Olivares, N., Ruiz-Arruza, I., Martinez-Berriotxoa, A., Egurbide, M.-V., & Aguirre, C.
- Venue
- Arthritis Research & Therapy
- Published
- 2009-07-15
- Volume
- 11
- Issue
- 4
- Pages
- R109-R109
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W2143645568
- Cited by
- 374
- References
- 25
- FWCI
- 10.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.